Table 5.
ICU Admissions post COVID-19 vaccination.
| Case | Gender | Age | Vaccine | Dose | Days between vaccine and ICU admission | Pre-ICU reported side effects | ICU diagnosis | Comorbidities |
|---|---|---|---|---|---|---|---|---|
| Mean ±SD | 38.4 ±13.8 | 8.2 ±3.8 | ||||||
| 1 | M | 32 | Oxford-AstraZeneca | 1 | 4 | - | Acute myocardial infarction | - |
| 2 | M | 32 | Oxford-AstraZeneca | 1 | 8 | Dyspnea -Fever above 39 -Headache -Hoarseness -Injection site pain -Wheezing -Fatigue | Pneumonia\ COVID-19 | - |
| 3 | F | 34 | Oxford-AstraZeneca | 1 | 14 | -Dizziness - Fever above 39 - Headache | Pneumonia\COVID-19 | - |
| 4 | F | 43 | Oxford-AstraZeneca | 1 | 10 | Dyspnea | Atherosclerosis | - |
| 5 | M | 51 | Oxford-AstraZeneca | 1 | 11 | Low fever | Acute respiratory failure | Chronic lung disease |
| 6 | F | 28 | Pfizer-BioNTech | 2 | 12 | Headache | Intracranial hemorrhage | - |
| 7 | F | 31 | Pfizer-BioNTech | 2 | 7 | - | Grand mal seizures | Hypertension |
| 8 | M | 39 | Pfizer-BioNTech | 1 | 10 | - | Guillain-Barré syndrome | - |
| 9 | F | 60 | Pfizer-BioNTech | 2 | 4 | - | Abnormal blood gas levels | - |
| 10 | M | 60 | Pfizer-BioNTech | 1 | 5 | -Anxiety - Fever above 39 | Septic shock | Chronic cardiovascular disease |